# A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Treprostinil Palmitil Inhalation Powder (TPIP) in Healthy Participants

> **NCT06091579** · PHASE1 · COMPLETED · sponsor: **Insmed Incorporated** · enrollment: 42 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **DRUG:** Treprostinil Palmitil Inhalation Powder
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06091579
- **Lead sponsor:** Insmed Incorporated
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-09-17
- **Primary completion:** 2021-01-12
- **Final completion:** 2021-01-12
- **Target enrollment:** 42 (ACTUAL)
- **Last updated:** 2023-10-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06091579

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06091579, "A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Treprostinil Palmitil Inhalation Powder (TPIP) in Healthy Participants". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT06091579. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*